Accurate imaging for Neuroendocrine Tumors (NETs), Pheochromocytoma, Paraganglioma, Medullary Thyroid Carcinoma and treatment planning using advanced Gallium-68 DOTA PET CT technology.
Please call our team at +91 8699572364 before visiting. Our staff will share the latest centre location, directions, parking guidance and appointment instructions.
Years Experience
PET Studies
Reporting*
Booking Support
Most patients are not advised to undergo a DOTA PET CT scan as the first test. It is usually recommended after your symptoms, examination, blood tests, and other imaging suggest the possibility of a neuroendocrine tumor (NET) or another condition where somatostatin receptor imaging can provide additional information.
Your doctor may refer you to a gastroenterologist, endocrinologist, oncologist, surgeon, or nuclear medicine specialist depending on your symptoms.
Blood tests can suggest the possibility of a neuroendocrine tumor, but they usually cannot determine the exact location or extent of disease. Imaging studies help identify where the abnormal tissue is located and whether it has spread.
Often the first imaging test to evaluate abdominal organs such as the liver, pancreas and gallbladder.
Provides detailed anatomical images and may identify masses, enlarged lymph nodes or metastatic disease.
Useful for evaluating soft tissues, the liver and pancreas, especially when additional anatomical detail is required.
When appropriate, a biopsy confirms the diagnosis and helps determine tumor type and grade.
After these findings are reviewed, your doctor may recommend a DOTA PET CT scan to assess somatostatin receptor expression, stage disease and support treatment planning.
Neuroendocrine tumors (NETs) are uncommon tumors that arise from neuroendocrine cells. These cells are found throughout the body and help regulate hormones. Some NETs grow slowly over many years, while others behave more aggressively. Identifying the type, location and extent of disease is important because treatment depends on these factors.
These tumors produce hormones that may cause symptoms such as flushing, diarrhea, stomach ulcers, low blood sugar or other hormone-related problems.
These tumors often produce few or no hormone-related symptoms and may be discovered only after imaging or because of pressure on nearby organs.
NETs can range from slow-growing to more aggressive forms. Tumor grade and other pathological findings help guide treatment.
Many neuroendocrine tumors express somatostatin receptors on their cell surface. Gallium-68 DOTA PET CT uses a tracer that binds to these receptors, allowing doctors to identify areas of abnormal uptake throughout the body. This information may assist with diagnosis, staging, treatment planning and follow-up in appropriate patients.
Not every patient with a suspected tumor requires a DOTA PET CT scan. The decision is made by the treating clinician after reviewing symptoms, examination findings, laboratory results, pathology and previous imaging.
Neuroendocrine tumors (NETs) can arise in different organs and behave differently. Some produce hormones and cause noticeable symptoms, while others remain silent until they are detected on imaging or during evaluation for another condition.
May be functional or non-functional. Some pancreatic NETs produce hormones such as insulin or gastrin, while others present as a pancreatic mass.
Often develops in the ileum and may be associated with carcinoid syndrome in selected patients.
Includes typical and atypical carcinoid tumors. Imaging helps determine the extent of disease.
May be detected during endoscopy or cross-sectional imaging and requires individualized evaluation.
Some are found incidentally after surgery, while others require additional staging investigations.
These neuroendocrine tumors can produce catecholamines and may require specialized functional imaging.
After a biopsy or surgery, the pathology report often includes the tumor grade and Ki-67 index. These findings help estimate how quickly the tumor cells are dividing and assist the treating team with management decisions.
| Grade | General Description | Clinical Meaning |
|---|---|---|
| G1 | Low-grade | Usually slower-growing tumors. |
| G2 | Intermediate-grade | Growth rate is between G1 and G3. |
| G3 | High-grade | Generally faster-growing tumors requiring specialist evaluation. |
The decision to perform a DOTA PET CT depends on several factors, including the suspected tumor type, pathology, prior imaging, and the clinical question your doctor needs answered. It is one component of a comprehensive diagnostic and treatment planning pathway.
A DOTA PET CT scan is usually requested after a structured clinical evaluation. The decision is based on your symptoms, physical examination, laboratory findings, pathology and other imaging studies—not on a single test alone.
Your doctor reviews your medical history, medications, family history, previous surgeries, prior imaging and performs a physical examination before deciding which investigations are appropriate.
| Investigation | Why it may be ordered |
|---|---|
| Chromogranin A | NET marker in selected patients |
| 5-HIAA* | Often a urine-based test for carcinoid syndrome |
| Calcitonin | When clinically indicated |
| CBC | General health assessment |
| LFT & KFT | Evaluate liver and kidney function |
| Blood Glucose | Baseline evaluation where appropriate |
*The choice of laboratory tests depends on the suspected condition.
CT and MRI provide excellent anatomical detail, but they do not always show whether a lesion expresses somatostatin receptors. A Ga-68 DOTA PET CT scan adds functional information that can help detect receptor-positive disease, evaluate its extent and assist with treatment planning in appropriately selected patients.
The final decision to perform a DOTA PET CT scan is made by the treating specialist after considering your complete clinical picture. Imaging results should always be interpreted together with laboratory tests, pathology findings and your medical history.
A DOTA PET CT report is interpreted together with your symptoms, laboratory tests, biopsy results and previous imaging. The scan should never be read in isolation.
Many neuroendocrine tumors express somatostatin receptors. Areas of increased tracer uptake may indicate receptor-positive disease and help determine whether additional evaluation or treatment planning is required.
The SUV is a quantitative measurement of tracer uptake. It is one piece of information used by the reporting physician and should always be interpreted in the clinical context.
The report may describe the suspected primary lesion, its location, size (from CT) and tracer uptake characteristics.
The report evaluates whether there is evidence of disease in lymph nodes, liver, bones or other organs.
Some organs normally show tracer uptake. Experienced Nuclear Medicine physicians distinguish expected physiological activity from abnormal findings.
When earlier CT, MRI or PET studies are available, they help assess response to treatment or changes over time.
| Term | Meaning |
|---|---|
| Lesion | An abnormal area identified on imaging. |
| Primary Tumor | The site where the tumor is believed to have started. |
| Metastasis | Spread of disease to another part of the body. |
| Lymph Node | Immune tissue that may be involved by disease. |
| Somatostatin Receptor | A protein that many NETs express and which DOTA tracers target. |
| Physiological Uptake | Expected normal tracer distribution. |
| SUV | A measurement of tracer uptake used as part of image interpretation. |
Do not try to diagnose yourself based only on your PET CT report. Your treating doctor combines the report with your history, examination, pathology and other investigations before recommending treatment or follow-up.
The purpose of a DOTA PET CT scan is not only to detect disease but also to help the multidisciplinary team choose the most appropriate treatment strategy. Decisions are based on the scan findings together with pathology, tumor grade, symptoms, laboratory results and the patient's overall health.
When the tumor is localized and suitable for surgery, DOTA PET CT helps define the extent of disease and supports surgical planning.
Peptide Receptor Radionuclide Therapy (PRRT) may be considered for selected patients whose tumors demonstrate sufficient somatostatin receptor expression on DOTA PET imaging.
Some patients receive somatostatin analogues, targeted therapies or other medicines depending on tumor type and specialist recommendations.
Chemotherapy may be appropriate for selected neuroendocrine tumors, particularly those with higher-grade or more aggressive features.
Radiation treatment may be recommended in specific situations to control symptoms or treat localized disease.
Repeat imaging may be advised to monitor treatment response or detect recurrence when clinically indicated.
A DOTA PET CT scan does not determine treatment by itself. Treatment decisions are individualized and are made after careful discussion between the patient and the treating medical team.
The role of Ga-68 DOTA PET CT depends on the suspected disease, pathology findings and the clinical question your doctor is trying to answer. The sections below explain some of the conditions where this imaging study may be considered.
Symptoms: Abdominal pain, weight loss, hormone-related symptoms or an incidental pancreatic mass.
Work-up: Blood tests, CT/MRI, biopsy when appropriate.
Role of DOTA PET: Assess receptor-positive disease, staging and treatment planning.
Symptoms: Abdominal pain, flushing, diarrhea or bowel obstruction.
Work-up: CT enterography, MRI, endoscopy or surgery depending on the presentation.
Role of DOTA PET: Detect primary and metastatic disease in suitable patients.
Symptoms: Persistent cough, wheezing, chest discomfort or incidental lung nodule.
Work-up: CT chest, bronchoscopy and pathology.
Role of DOTA PET: Evaluate receptor expression and disease extent.
Symptoms: Episodes of high blood pressure, headache, sweating and palpitations.
Work-up: Biochemical testing, CT/MRI and specialist assessment.
Role of DOTA PET: Functional imaging in selected clinical scenarios.
Symptoms: Variable depending on location and hormone secretion.
Work-up: Imaging, laboratory evaluation and pathology when available.
Role of DOTA PET: Whole-body assessment and staging in appropriate patients.
Symptoms: Neck lump or elevated calcitonin in selected patients.
Work-up: Ultrasound, calcitonin, biopsy and cross-sectional imaging.
Role of DOTA PET: May provide additional information in selected recurrent or metastatic cases.
The same diagnosis does not always require the same imaging test. Your treating team selects investigations based on symptoms, pathology, previous imaging and the specific clinical question that needs to be answered.
Preparation instructions may vary depending on your medical condition and your doctor's recommendations. Always follow the guidance provided by your imaging centre and treating specialist.
Appointment confirmation and review of your clinical information.
A small intravenous injection of the Ga-68 DOTA tracer.
The tracer circulates through the body before imaging.
You lie still while the scanner acquires images.
Images are interpreted by a Nuclear Medicine physician.
The scan uses a carefully controlled amount of radioactive tracer. The benefits and risks are considered before the examination is recommended.
Drink fluids unless advised otherwise and follow any instructions provided by the imaging team regarding routine activities.
Call +91 8699572364 before travelling. The patient support team can provide the latest centre address, directions, parking guidance and appointment assistance.
Speak with the patient support team to understand preparation requirements, appointment availability and documentation needed for your visit.
Call 8699572364Different imaging tests answer different clinical questions. Your doctor selects the most appropriate study based on the suspected disease, pathology, previous imaging and treatment goals.
DOTA PET: Commonly used for well-differentiated, somatostatin receptor-positive neuroendocrine tumors.
FDG PET: Often used for cancers with higher glucose metabolism and selected higher-grade NETs.
DOTA PET: Evaluates neuroendocrine tumors.
PSMA PET: Primarily used in prostate cancer imaging.
DOTA PET: Focuses on somatostatin receptor imaging.
DOPA PET: May be preferred for selected neurological disorders and certain neuroendocrine indications.
DOTA PET: Best suited for receptor-positive NET evaluation.
FAPI PET: An emerging tracer being studied across multiple tumor types.
MRI provides excellent anatomical detail, while DOTA PET CT provides functional receptor imaging. They are often complementary.
CT shows anatomy, whereas DOTA PET CT combines CT anatomy with molecular imaging to evaluate receptor-positive disease.
| Clinical Question | Often Considered |
|---|---|
| Neuroendocrine Tumor Assessment | Ga-68 DOTA PET CT |
| Higher Glucose Metabolism Tumors | FDG PET CT |
| Prostate Cancer Imaging | PSMA PET CT |
| Soft Tissue Anatomy | MRI |
| Initial Structural Assessment | CT Scan |
These imaging studies are complementary rather than interchangeable. The most appropriate test depends on your diagnosis, pathology, prior investigations and the clinical question your treating team is trying to answer.
Some neuroendocrine tumors (NETs) produce excessive amounts of hormones, leading to specific symptoms. Identifying the hormone involved, confirming the diagnosis with appropriate laboratory tests, and selecting the right imaging study are important steps in treatment planning.
Common symptoms: Recurrent low blood sugar, sweating, tremors, confusion and fainting.
Typical work-up: Blood glucose, insulin studies, CT/MRI, endoscopic ultrasound and pathology when required.
Role of DOTA PET CT: May be useful in selected patients depending on tumor characteristics and specialist advice.
Common symptoms: Severe acidity, recurrent peptic ulcers and chronic diarrhea.
Typical work-up: Gastrin levels, endoscopy, CT/MRI and biopsy where appropriate.
Role of DOTA PET CT: Helps evaluate receptor-positive disease and determine its extent in selected cases.
Common symptoms: Profuse watery diarrhea, dehydration and electrolyte imbalance.
Typical work-up: VIP level, blood tests and cross-sectional imaging.
Role of DOTA PET CT: Supports localization and staging in appropriate patients.
Common symptoms: Weight loss, diabetes, skin rash and nutritional deficiencies.
Typical work-up: Glucagon testing, CT/MRI and pathology.
Role of DOTA PET CT: May assist with staging and treatment planning.
Common symptoms: Diabetes, gallstones, diarrhea and weight loss.
Typical work-up: Hormonal evaluation, imaging and biopsy when indicated.
Role of DOTA PET CT: Evaluates somatostatin receptor expression and disease distribution.
Common symptoms: Facial flushing, chronic diarrhea, wheezing and heart valve complications in some patients.
Typical work-up: 5-HIAA testing, blood investigations, CT/MRI and pathology.
Role of DOTA PET CT: Helps identify receptor-positive primary and metastatic disease in suitable patients.
No single blood test or scan confirms every neuroendocrine tumor. Doctors combine your medical history, examination, laboratory findings, pathology and imaging studies to reach a diagnosis and develop an individualized treatment plan.
These questions cover preparation, safety, reports and common concerns. Always follow the advice of your treating doctor and imaging team.
It may be recommended when your doctor needs additional information about a suspected or confirmed neuroendocrine tumor, its extent, or whether it expresses somatostatin receptors.
Yes. A referral from your treating doctor is generally required.
Bring previous PET, CT, MRI, ultrasound, pathology reports and relevant blood investigations whenever available.
Continue or stop medicines only according to the instructions given by your treating doctor or imaging centre.
Comfortable clothing without unnecessary metal accessories is generally recommended.
Most people only feel the brief discomfort of the intravenous injection. The scan itself is painless.
The total visit varies depending on preparation, tracer uptake time and image acquisition.
Yes. Remaining still helps produce clearer images.
A companion can usually accompany you to the centre, although access to scanning areas may be restricted.
A qualified Nuclear Medicine physician reviews the images and prepares the report.
Reporting times vary depending on the clinical situation and reporting workflow.
Most patients can return to routine activities unless advised otherwise.
Follow the instructions provided by the imaging team regarding hydration and routine activities.
Call +91 8699572364. The patient support team can provide the latest address, directions, parking information and appointment assistance.